Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy

NCT02770261 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

219

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension
Cholesterolemia

Interventions

DRUG: DP-R208
DRUG: Candesartan32mg
DRUG: Rosuvastatin 20mg
DRUG: DP-R208 Placebo
DRUG: Candesartan32mg Placebo
DRUG: Rosuvastatin 20mg Placebo

Sponsor

Alvogen Korea